Literature DB >> 12689935

Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates.

Andras Gruber1, Stephen R Hanson.   

Abstract

Thrombin, generated through activation of factor XI (FXI) and/or tissue factor (TF)-factor VIIa, is essential for thrombosis and hemostasis. We investigated the role of FXI-dependent thrombus propagation under arterial flow conditions producing rapid thrombus growth that, after the initiation phase, could limit the availability of TF at the blood/thrombus interface. Thrombosis was initiated by knitted dacron or TF-presenting teflon grafts deployed into arteriovenous shunts in baboons treated with antihuman FXI antibody (aFXI). Although aFXI did not prevent thrombus initiation, it markedly reduced intraluminal thrombus growth on both surfaces. The antithrombotic effect of aFXI was comparable with that of heparin at doses that significantly prolonged the partial thromboplastin time (APTT), prothrombin time (PT), and bleeding time (BT). aFXI also prolonged the APTT, but the PT and BT were unaffected. Thus, antithrombotic targeting of FXI might inhibit thrombosis with relatively modest hemostatic impairment versus strategies targeting other coagulation factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12689935     DOI: 10.1182/blood-2003-01-0324

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively.

Authors:  Mikhail A Panteleev; Mikhail V Ovanesov; Dmitrii A Kireev; Aleksei M Shibeko; Elena I Sinauridze; Natalya M Ananyeva; Andrey A Butylin; Evgueni L Saenko; Fazoil I Ataullakhanov
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

Review 2.  Endothelial outgrowth cells: function and performance in vascular grafts.

Authors:  Jeremy J Glynn; Monica T Hinds
Journal:  Tissue Eng Part B Rev       Date:  2013-10-10       Impact factor: 6.389

Review 3.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

4.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

5.  Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis.

Authors:  Erik I Tucker; Norah G Verbout; Philberta Y Leung; Sawan Hurst; Owen J T McCarty; David Gailani; András Gruber
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

Review 6.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

Review 7.  Factor XI and XII as antithrombotic targets.

Authors:  Felicitas Müller; David Gailani; Thomas Renné
Journal:  Curr Opin Hematol       Date:  2011-09       Impact factor: 3.284

Review 8.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 9.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

10.  Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.

Authors:  Christina U Lorentz; Norah G Verbout; Michael Wallisch; Matthew W Hagen; Joseph J Shatzel; Sven R Olson; Cristina Puy; Monica T Hinds; Owen J T McCarty; David Gailani; András Gruber; Erik I Tucker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.